Phase I trial of GTP-004 in healthy volunteers
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 26 Mar 2018
At a glance
- Drugs Ondansetron/pyridostigmine (Primary) ; Pyridostigmine
- Indications Myasthenia gravis
- Focus Adverse reactions; Proof of concept
- 26 Mar 2018 Results presented in a GT Biopharma media release.
- 09 Jan 2018 Status changed from recruiting to active, no longer recruiting, according to a GT Biopharma media release.
- 09 Jan 2018 According to a GT Biopharma media release, dosing of patients has been completed.